NIKINasdaqMeasuring & Controlling Devices, NECFiscal year ends December 31

Niki BioSolutions, Inc.

Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026

$2.08+0.05 (+2.46%)

Close on Oct 19, 2026

Market cap: $16.66M
P/E (TTM): –
Dividend yield: –

Niki BioSolutions, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Depreciation & Amortization	–	0.26	1.13	1.21	1.19	1.33	1.30	0.68
Stock-Based Compensation	–	–	1.27	1.65	1.68	1.48	1.61	–
Change in Accounts Receivable	–	0.04	0.13	-0.10	-0.02	-0.02	-0.04	0.00
Change in Inventory	–	–	0.01	0.01	0.00	0.00	0.00	-0.03
Change in Accounts Payable	-0.03	-0.42	0.40	1.92	–	–	0.99	0.06
Operating Cash Flow	-1.84	-1.19	-7.72	-12	-15	-16	-13	-10
Capital Expenditures	–	–	0.00	-0.19	-0.13	-0.16	-0.84	-5.65
Acquisitions	–	–	–	–	-0.11	–	–	–
Sale of Property, Plant & Equipment	–	0.06	0.02	–	–	1.05	–	–
Sale & Maturity of Investments	–	–	0.09	–	20	0.95	1.00	0.00
Investing Cash Flow	–	0.06	0.62	2.44	17	1.84	-0.11	-6.06
Stock Issued	3.07	–	1.58	–	4.00	17	–	11
Financing Cash Flow	4.42	–	4.09	6.63	2.78	12	-7.32	25
Net Change in Cash	2.58	-1.13	-3.01	-3.25	4.64	-1.67	-21	9.38
Free Cash Flow	–	–	-7.73	-13	-15	-16	-14	-16
Interest Paid	–	–	0.09	0.06	0.27	0.13	0.56	0.61

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -6.2%

Financial strength

Current ratio: 0.78
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 75.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.72
Dividend yield: –